A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene-related peptide and beyond.

119 More patients reported immediate and delayed headaches after AM (50% [six of 12] and 58.3% [seven of 12] of patients, respectively) than placebo (8.3% [one of 12] and 33.3% [four of 12] of patients, respectively), although this difference did not reach statistical significance. 119 It is worth noting that the nocebo migraine response rate in this study (33.3%) is higher than the average nocebo response rate in migraine provocation studies (95% confidence interval of 2.5%–15.5%) 120 and it is possible that this high nocebo rate may have confounded interpretation of results.

also in 111,027 other papers